Paul Bingham and Mike Morris, former FBI cybersecurity agents, explain how they're training the next wave of defenders to handle AI threats.

Rallybio has agreed to sell its interest in a drug-development plan seeking to treat a rare genetic bone disease to its joint-venture partner Recursion Pharmaceuticals for up to $25 million.

While AI-driven approaches tout increased speed and lower costs, commercial interests compromise scientific collaboration.

Former Google CEO Eric Schmidt warns that Artificial Superintelligence (ASI), surpassing human intelligence, is imminent. He ...